Simulations Plus (SLP) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
9 Jul, 2026Executive summary
Q3 FY26 revenue rose 7% year-over-year to $21.9M, driven by a 20% increase in services revenue, while software revenue was flat.
Gross margin improved to 69% from 64% in the prior year quarter, reflecting lower software amortization and operational efficiencies.
Net income was $3.6M for the quarter, reversing a net loss of $67.3M in Q3 FY25, with diluted EPS of $0.18 and adjusted diluted EPS of $0.30.
A definitive merger agreement was signed to be acquired by Altaris for $18.50 per share in cash, with closing expected in Q4 2026.
Trailing twelve months (TTM) revenue was $82.1M, a 2% increase year-over-year, with TTM adjusted diluted EPS at $0.88.
Financial highlights
Q3 FY26 adjusted EBITDA margin was 36%, with adjusted EBITDA of $7.9M; nine-month adjusted EBITDA was $20.2M (31% of revenue).
Q3 FY26 gross margin was 69%, up from 64% in Q3 FY25; gross profit for the quarter was $15.1M.
YTD FY26 revenue grew 5% to $64.6M, with net income of $8.8M and adjusted EBITDA of $20.2M.
Cash and short-term investments totaled $50.0M as of May 31, 2026.
R&D expense increased 180% in Q3 and 89% for nine months, reflecting investment in cloud and AI-enabled platforms.
Outlook and guidance
Fiscal 2026 guidance projects total revenue of $79M–$82M, 0%–4% growth, software revenue mix of 57%–62%, adjusted EBITDA margin of 26%–30%, and adjusted diluted EPS of $0.75–$0.85.
Management expects sufficient liquidity for the next 12 months, with $35.3M in cash and $14.7M in short-term investments as of May 31, 2026.
Pending merger restricts certain capital allocation activities until closing.
Continued investment in R&D and cloud/AI capabilities is planned.
Management remains focused on execution and client delivery during the transition to new ownership.
Latest events from Simulations Plus
- Shareholders to vote on $18.50/share cash merger, with board unanimous support and 26% premium.SLP
Proxy filing9 Jul 2026 - FY24 revenue up 18% to $70M; FY25 guidance strong with Pro-ficiency driving growth.SLP
Q4 20249 Jul 2026 - FY25 guidance targets $90M-$93M revenue, 31%-33% EBITDA margin, and expanded market reach.SLP
Stephens 26th Annual Investment Conference | NASH20248 Jul 2026 - Q1 revenue fell 3% to $18.4M as services rose 16%, software dropped 17%, and guidance was reaffirmed.SLP
Q1 20268 Jul 2026 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement8 Jul 2026 - OBESITYsym predicts weight loss and nausea for obesity drugs, validated across diverse populations.SLP
Status update23 Jun 2026 - Q2 2026 revenue up 8% to $24.3M, with higher margins and strong outlook despite EPS guidance cut.SLP
Q2 202610 Apr 2026 - Integrated AI ecosystem and cross-selling drive future growth, with major upside in FY 2027.SLP
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - All proposals passed with strong support; no shareholder questions were raised.SLP
AGM 202612 Feb 2026